Table 4.
Common adverse events reported in relation with the treatment group.
| Adverse Event | Metformin group (N = 36) | Control group (N = 38) | ||||||
|---|---|---|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Anemia | 14 (38.89%) | 8 (22.22%) | 2 (5.56%) | 0 (0.00%) | 13 (34.21%) | 10 (26.32%) | 3 (7.89%) | 0 (0.00%) |
| Neutropenia | 4 (11.11%) | 5 (13.89%) | 2 (5.56%) | 0 (0.00%) | 3 (7.89%) | 5 (13.16%) | 3 (7.89%) | 0 (0.00%) |
| Febrile Neutropenia | 1 (2.78%) | 1 (2.78%) | 1 (2.78%) | 0 (0.00%) | 0 (0.00%) | 2 (5.26%) | 0 (0.00%) | 0 (0.00%) |
| Thrombocytopenia | 1 (2.78%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
| Nausea | 11 (30.56%) | 17 (47.22%) | 2 (5.56%) | 0 (0.00%) | 12 (31.58%) | 15 (39.47%) | 1 (2.63%) | 0 (0.00%) |
| Vomiting | 9 (25.00%) | 15 (41.67%) | 0 (0.00%) | 0 (0.00%) | 13 (34.21%) | 11 (28.95%) | 0 (0.00%) | 0 (0.00%) |
| Constipation | 3 (8.33%) | 1 (2.78%) | 0 (0.00%) | 0 (0.00%) | 7 (18.42%) | 2 (5.26%) | 0 (0.00%) | 0 (0.00%) |
| Diarrhea | 12 (33.33%) | 5 (13.89%) | 1 (2.78%) | 0 (0.00%) | 14 (36.84%) | 1 (2.63%) | 0 (0.00%) | 0 (0.00%) |
| Abdominal pain | 6 (16.67%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 5 (13.16%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
| ALT/AST increased | 5 (13.89%) | 1 (2.78%) | 0 (0.00%) | 0 (0.00%) | 4 (10.53%) | 1 (2.63%) | 0 (0.00%) | 0 (0.00%) |
| Acute kidney injury | 1 (2.78%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 2 (5.26%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
| Fatigue | 20 (55.56%) | 12 (33.33%) | 3 (8.33%) | 0 (0.00%) | 24 (63.16%) | 9 (23.68%) | 3 (7.89%) | 0 (0.00%) |
| Dizziness | 6 (16.67%) | 2 (5.56%) | 0 (0.00%) | 0 (0.00%) | 4 (10.53%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
| Arthralgia | 4 (11.11%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | 7 (18.42%) | 1 (2.63%) | 0 (0.00%) | 0 (0.00%) |
| Myalgia | 5 (13.89%) | 2 (5.56%) | 0 (0.00%) | 0 (0.00%) | 7 (18.42%) | 3 (7.89%) | 0 (0.00%) | 0 (0.00%) |
| Bone pain | 5 (13.89%) | 1 (2.78%) | 0 (0.00%) | 0 (0.00%) | 10 (26.32%) | 1 (2.63%) | 0 (0.00%) | 0 (0.00%) |
| Sensory neuropathy | 11 (30.56%) | 5 (13.89%) | 0 (0.00%) | 0 (0.00%) | 17 (44.74%) | 8 (21.05%) | 0 (0.00%) | 0 (0.00%) |
| Dyspnea | 4 (11.11%) | 3 (8.33%) | 0 (0.00%) | 0 (0.00%) | 4 (10.53%) | 1 (2.63%) | 0 (0.00%) | 0 (0.00%) |
| Alopecia | 2 (5.56%) | 34 (94.44%) | 0 (0.00%) | 0 (0.00%) | 3 (7.89%) | 35 (92.11%) | 0 (0.00%) | 0 (0.00%) |
| Skin rash | 5 (13.89%) | 2 (5.56%) | 0 (0.00%) | 0 (0.00%) | 3 (7.89%) | 3 (7.89%) | 0 (0.00%) | 0 (0.00%) |
ALT/AST Alanine aminotransferase/Aspartate aminotransferase.